Bayer gets €3 billion in Apollo deal for contraceptives unit

Bayer secured €3.0B ($3.4B) in equity from Apollo-managed funds via a transaction linked to its LARC (long-acting reversible contraceptives) business, targeting a stronger capital structure while preserving control. The capital raise is a supportive balance-sheet move, likely to be viewed positively by investors, but it’s not a full company re-rating event.

Analysis

Bayer secured €3.0B ($3.4B) in equity from Apollo-managed funds via a transaction linked to its LARC (long-acting reversible contraceptives) business, targeting a stronger capital structure while preserving control. The capital raise is a supportive balance-sheet move, likely to be viewed positively by investors, but it’s not a full company re-rating event.